Safety and Efficacy of Ultra-Low LDL Cholesterol via PCSK9 Inhibitors
This article analyzes the safety and effectiveness of achieving extremely low LDL cholesterol levels using PCSK9 inhibitors, drawing parallels with individuals possessing genetic mutations that naturally result in LDL levels around 30 mg/dL. These individuals typically enjoy exceptional longevity, suggesting that very low cholesterol is not inherently harmful. Clinical data indicates that reducing LDL below 60 mg/dL for primary prevention and around 30 mg/dL for secondary prevention significantly lowers cardiovascular event risks, potentially approaching zero incidence. Studies show no adverse side effects or impaired hormone production even when LDL drops below 15 mg/dL, countering concerns about steroid hormone synthesis. The text emphasizes that humans evolved with lower baseline cholesterol levels, making current high averages abnormal. While PCSK9 inhibitors effectively lower LDL without observed offsetting risks in trials lasting up to six years, the author notes the need for longer-term follow-up data to rule out delayed side effects, similar to the late discovery of diabetes risks with statins. Additionally, the high cost of these drugs, approximately $14,000 annually, is highlighted as a significant barrier. The overall conclusion supports aggressive LDL reduction while acknowledging the necessity for continued long-term safety monitoring.
Wire timeline
Safety and Efficacy of Ultra-Low LDL Cholesterol via PCSK9 Inhibitors
This article analyzes the safety and effectiveness of achieving extremely low LDL cholesterol levels using PCSK9 inhibitors, drawing parallels with individuals possessing genetic mutations that naturally result in LDL levels around 30 mg/dL. These individuals typically enjoy exceptional longevity, suggesting that very low cholesterol is not inherently harmful. Clinical data indicates that reducing LDL below 60 mg/dL for primary prevention and around 30 mg/dL for secondary prevention significantly lowers cardiovascular event risks, potentially approaching zero incidence. Studies show no adverse side effects or impaired hormone production even when LDL drops below 15 mg/dL, countering concerns about steroid hormone synthesis. The text emphasizes that humans evolved with lower baseline cholesterol levels, making current high averages abnormal. While PCSK9 inhibitors effectively lower LDL without observed offsetting risks in trials lasting up to six years, the author notes the need for longer-term follow-up data to rule out delayed side effects, similar to the late discovery of diabetes risks with statins. Additionally, the high cost of these drugs, approximately $14,000 annually, is highlighted as a significant barrier. The overall conclusion supports aggressive LDL reduction while acknowledging the necessity for continued long-term safety monitoring.
NutritionFacts.org